NOK 1.9
(-5.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | -5730.00 NOK | -100.01% |
2022 | 49.03 Million NOK | 7.21% |
2021 | 45.73 Million NOK | 75.76% |
2020 | 26.02 Million NOK | 69.89% |
2019 | 15.31 Million NOK | 51.63% |
2018 | 10.1 Million NOK | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 14.88 Million NOK | 0.0% |
2024 Q1 | 14.88 Million NOK | -0.92% |
2023 Q4 | 15.02 Million NOK | 0.0% |
2023 FY | -5730.00 NOK | -100.01% |
2023 Q1 | - NOK | -100.0% |
2023 Q3 | 15.02 Million NOK | 0.0% |
2023 Q2 | - NOK | 0.0% |
2022 Q4 | 14.52 Million NOK | 0.0% |
2022 FY | 49.03 Million NOK | 7.21% |
2021 FY | 45.73 Million NOK | 75.76% |
2020 FY | 26.02 Million NOK | 69.89% |
2019 FY | 15.31 Million NOK | 51.63% |
2018 FY | 10.1 Million NOK | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Aqua Bio Technology ASA | 18.46 Million NOK | 100.031% |
ArcticZymes Technologies ASA | 97.26 Million NOK | 100.006% |
BerGenBio ASA | 192.17 Million NOK | 100.003% |
Hofseth BioCare ASA | 156.04 Million NOK | 100.004% |
PCI Biotech Holding ASA | 25.23 Million NOK | 100.023% |
Thor Medical ASA | 7.16 Million NOK | 100.08% |
Ultimovacs ASA | 215.73 Million NOK | 100.003% |